Leronlimab Safety and Brain Inflammation in Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older with diagnosed mild-to-moderate memory loss or Alzheimer's disease (confirmed by a cognitive test)
- Able to complete memory and thinking tests, including a specific screening test (MoCA score above 11)
- Normal or non-concerning heart rhythm on an ECG test
- If taking Alzheimer's or brain-related medications, must be on the same dose for at least 12 weeks before starting the trial
- Have a study partner (family member or friend) who can help support you and provide information about your condition
- Able to undergo MRI and PET brain scans without contraindications (no pacemakers, metal implants, or severe claustrophobia)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who are taking or have taken lecanemab (a medication for Alzheimer's disease). It aims to gather more information about the treatment's effects in real-world settings.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
This trial tests whether a monoclonal antibody drug can help people with early Alzheimer's disease or mild cognitive impairment. The drug targets amyloid plaques in the brain, which are detected using a special PET scan before treatment.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hear when a new Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.